Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus

Systemic sclerosis and systemic lupus erythematosus represent two distinct autoimmune diseases belonging to the group of connective tissue disorders. Despite the great progress in the basic science, this progress has not been translated to the development of novel therapeutic approaches that can rad...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2022-07, Vol.15 (8), p.936
Main Authors: Kotyla, Przemysław, Gumkowska-Sroka, Olga, Wnuk, Bartosz, Kotyla, Kacper
Format: Article
Language:English
Subjects:
Antigens
Biological products
Chemokines
Chronic illnesses
Connective tissue diseases
cytokine network
Cytokines
Drug therapy
Drugs
Immune system
Immunocompetence
Kinases
Proteins
Psoriatic arthritis
Review
Rheumatoid arthritis
Scleroderma (Disease)
Systemic lupus erythematosus
Systemic scleroderma
systemic sclerosis JAK inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic sclerosis and systemic lupus erythematosus represent two distinct autoimmune diseases belonging to the group of connective tissue disorders. Despite the great progress in the basic science, this progress has not been translated to the development of novel therapeutic approaches that can radically change the face of these diseases. The discovery of JAK kinases, which are tyrosine kinases coupled with cytokine receptors, may open a new chapter in the treatment of so far untreatable diseases. Small synthetic compounds that can block Janus kinases and interact directly with cytokine signalling may provide therapeutic potential in these diseases. In this review, we discuss the therapeutic potential of Jak kinases in light of the cytokine network that JAK kinases are able to interact with. We also provide the theoretical background for the rationale of blocking cytokines with specific JAK inhibitors.
ISSN:1424-8247
1424-8247
DOI:10.3390/ph15080936